INVASIVE INTERVENTIONS IN STRUCTURAL HEART DISEASES: COMPREHENSIVE TECHNIQUES

Invasive Interventions in Structural Heart Diseases-kapak

COMPLICATIONS AND MANAGEMENT OF ATRIAL SEPTAL PROCEDURES

Murat Özmen

Health Science University, Erzurum Regional Training and Research Hospital, Department of Cardiology, Erzurum, Türkiye

Özmen M. Complications and Management of Atrial Septal Procedures. In: Tanık VO, Özlek B editors. Invasive Interventions in Structural Heart Diseases: Comprehensive Techniques. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.437-445.

ABSTRACT

Atrial septal defects (ASD) are one of the most common congenital heart diseases in adults. Another important condition, patent foramen ovale (PFO), is found in up to 25% of the population. It is important to diagnose these diseases. There is a wide spectrum of clinical presentations, with right heart failure and severe pulmonary vascular disease in undiagnosed asymptomatic individuals. After ASD and PFO are diagnosed, they should be closed with appropriate indications. Surgery or wig closure is an option, especially rather than medical treatment. ASD and PFO can be closed surgically. In addition to surgical treatment, short-term and long-term complications may occur in lesions closed with devices. Our current knowledge about these complications and their rates is limited. In this section, our aim will be to examine the complications that may arise from ASD and PFO closure and to discuss appropriate treatment modalities.

Keywords: Atrial septal defect; Patent foramen ovale; Treatment; Complication; Management

Referanslar

  1. Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation. 2014;130(9):749-56. [Crossref]  [PubMed]
  2. Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM,et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(14):e637-e697. Erratum in: Circulation. 2019;139(14):e831-e832. [Crossref]  [PubMed]
  3. Hara, H., Virmani, R., Ladich, E., Mackey-Bojack, S., Titus, J., Reisman, M., et al . Patent foramen ovale: current pathology, pathophysiology, and clinical status. Journal of the American College of Cardiology, 2005;46(9):1768-1776. [Crossref]  [PubMed]
  4. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clinic Proceedings. 1984;59:17-20. [Crossref]  [PubMed]
  5. Meissner I, Whisnant JP, Khandheria BK, Spittell PC, O'Fallon WM, Pascoe RD, et al. Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Stroke Prevention: Assessment of Risk in a Community. Mayo Clinic Proceedings. 1999;74:862-869. [Crossref]  [PubMed]
  6. Wilmshurst PT, Ellis BG, Jenkins BS. Paradoxical gas embolism in a scuba diver with an atrial septal defect. Br Med J 1986;293:1277. [Crossref]  [PubMed]  [PMC]
  7. Liou K, Wolfers D, Turner R, et al. Patent foramen ovale influences the presentation of decompression illness in SCUBA divers. Heart Lung Circ. 2015;24(1):26-31. [Crossref]  [PubMed]
  8. Kerut EK, Norfleet WT, Plotnick GD, Giles TD. Patent foramen ovale: a review of associated conditions and the impact of physiological size. J Am Coll Cardiol. 2001;38(3):613-623. [Crossref]  [PubMed]
  9. Clark E. B. Pathogenetic mechanisms of congenital cardiovascular malformations revisited. Seminars in perinatology. 1996;20(6):465-472. [Crossref]  [PubMed]
  10. Ho, S. Y., McCarthy, K. P., & Rigby, M. L. Morphological features pertinent to interventional closure of patent oval foramen. Journal of interventional cardiology. 2003;16(1), 33-38. [Crossref]  [PubMed]
  11. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59(1):17-20. [Crossref]  [PubMed]
  12. Murphy JG, Gersh BJ, McGoon MD, et al. Long-term outcome after surgical repair of isolated atrial septal defect. Follow-up at 27 to 32 years. N Engl J Med. 1990;323(24):1645-1650. [Crossref]  [PubMed]
  13. Schneider B, Bauer R. Is surgical closure of patent foramen ovale the gold standard for treating interatrial shunts? An echocardiographic follow-up study. J Am Soc Echocardiogr. 2005;18(12):1385-1391. [Crossref]  [PubMed]
  14. Fraisse A, Latchman M, Sharma SR, et al. Atrial septal defect closure: indications and contra-indications. J Thorac Dis. 2018;10(Suppl 24):S2874-S2881. [Crossref]  [PubMed]  [PMC]
  15. Geva T, Martins JD, Wald RM. Atrial septal defects. Lancet. 2014;383(9932):1921-1932. [Crossref]  [PubMed]
  16. Bradley EA, Ammash N, Martinez SC, et al. "Treat-to-close": Non-repairable ASD-PAH in the adult: Results from the North American ASD-PAH (NAAP) Multicenter Registry. Int J Cardiol. 2019;291:127-133. [Crossref]  [PubMed]
  17. England N. Clinical commissioning policy: percutaneous patent foraman ovale closure for the prevention of recurrent cerebral embolic stroke in adults (around age 60 years and under Publication Approval Reference: 000826. NHS England, 2019. [Link]
  18. Yang MC, Wu JR. Recent review of transcatheter closure of atrial septal defect. Kaohsiung J Med Sci. 2018;34(7):363-369. [Crossref]  [PubMed]
  19. Merkler AE, Gialdini G, Yaghi S, et al. Safety Outcomes After Percutaneous Transcatheter Closure of Patent Foramen Ovale. Stroke. 2017;48(11):3073-3077. [Crossref]  [PubMed]  [PMC]
  20. Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366(11):991-999. [Crossref]  [PubMed]
  21. Krumsdorf U, Ostermayer S, Billinger K, et al. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol. 2004;43(2):302-309. [Crossref]  [PubMed]
  22. Chambers J, Seed PT, Ridsdale L. Association of migraine aura with patent foramen ovale and atrial septal aneurysms. Int J Cardiol. 2013;168(4):3949-3953. [Crossref]  [PubMed]
  23. Agarwal SK, Ghosh PK, Mittal PK. Failure of devices used for closure of atrial septal defects: mechanisms and management. J Thorac Cardiovasc Surg 1996;112:21-6 [Crossref]  [PubMed]
  24. Deniz Ç, Canpolat U, Aytemir K. Percutaneous Retrieval of an Atrial Septal Defect Closure Device Embolized to the Abdominal Aorta. Abdominal Aortaya Embolize Olan Atriyal Septal Defekt Kapama Cihazının Perkütan Yolla Çıkarılması. Turk Kardiyol Dern Ars. 2024;52(8):617-618. [Crossref]  [PubMed]
  25. Levi DS, Moore JW. Embolization and retrieval of the Amplatzer septal occluder. Catheter Cardiovasc Interv 2004;61:543-7. [Crossref]  [PubMed]
  26. Balbi M, Pongiglione G, Bezante GP. Percutaneous rescue of left ventricular embolized Amplatzer septal occluder device. Catheter Cardiovasc Interv 2008; 72:559-62. [Crossref]  [PubMed]
  27. Batta A, Naganur S, Rajan A, Ary KA, Gawalkar A, Barwad P. Retrieval and repositioning of an embolized atrial septal defect closure device using a gooseneck snare. Egypt Heart J. 2021;73(1):51. [Crossref]  [PubMed]  [PMC]
  28. Pala S, Açar G, Tigen K, Kırma C. Percutaneous retrieval of an interatrial septal occluder device embolized into the aortic arch. Turk Kardiyol Dern Ars. 2010;38(7):502-504. [PubMed]
  29. Rana BS, Shapiro LM, McCarthy KP, Ho SY. Three-dimensional imaging of the atrial septum and patent foramen ovale anatomy: defining the morphological phenotypes of patent foramen ovale. Eur J Echocardiogr. 2010;11(10):19-25. [Crossref]  [PubMed]
  30. Kovacevic M, Atanaskovic M, Obradovic K, et al. Embolization of Patent Foramen Ovale Closure Device-Rare Complication and Unique Management Approach. Medicina (Kaunas). 2024;60(5):717. Published 2024 Apr 26. [Crossref]  [PubMed]  [PMC]
  31. Levi D.S., Moore J.W. Embolization and retrieval of the Amplatzer septal occluder. Catheter. Cardiovasc. Interv. Off. J. Soc. Card. Angiogr. Interv. 2004;61:543-547. [Crossref]  [PubMed]
  32. Goel SS, Aksoy O, Tuzcu EM, Krasuski RA, Kapadia SR. Embolization of patent foramen ovale closure devices: incidence, role of imaging in identification, potential causes, and management. Tex Heart Inst J. 2013;40(4):439-444. [PubMed]
  33. Mair J., Müller S., Bauer A. Unexpected early migration of a patent foramen ovale occluder. Wien. Klin. Wochenschr. 2021;133:806-807. [Crossref]  [PubMed]  [PMC]
  34. Levi DS, Moore JW. Embolization and retrieval of the Amplatzer septal occluder. Catheter Cardiovasc Interv. 2004;61(4):543-547. [Crossref]  [PubMed]
  35. Abaci A, Unlu S, Alsancak Y, Kaya U, Sezenoz B. Short and long term complications of device closure of atrial septal defect and patent foramen ovale: meta-analysis of 28,142 patients from 203 studies. Catheter Cardiovasc Interv. 2013;82(7):1123-38. [Crossref]  [PubMed]
  36. Taggart NW, Dearani JA, Hagler DJ. Late erosion of an Amplatzer septal occluder device 6 years after placement. J Thorac Cardiovasc Surg. 2011;142(1):221-222. [Crossref]  [PubMed]
  37. Jalal Z., Hascoet S., Baruteau A. E., Iriart X., Kreitmann B., Boudjemline Y., et al. Long-term Complications After Transcatheter Atrial Septal Defect Closure: A Review of the Medical Literature. The Canadian journal of cardiology, 2016;32(11):1315.e11-1315.e18. [Crossref]  [PubMed]